Literature DB >> 7743802

Successful immunization against Acanthamoeba keratitis in a pig model.

H Alizadeh1, Y He, J P McCulley, D Ma, G L Stewart, M Via, E Haehling, J Y Niederkorn.   

Abstract

The feasibility of inducing protective immunity to Acanthamoeba keratitis was tested in a pig model. Experiments were designed to determine if ocular infection with Acanthamoeba trophozoites would elicit protection against reinfection. Additional experiments examined whether injection of parasite antigens either intramuscularly, subconjunctivally, or by both routes would induce immunity. Therefore, four groups of animals were examined: (a) pigs that had resolved a primary corneal infection with Acanthamoeba; (b) pigs immunized intramuscularly; (c) pigs immunized subconjunctivally; and (d) pigs immunized intramuscularly and subconjunctivally. Animals were subsequently challenged with parasite-laden soft contact lenses and observed clinically for the appearance of Acanthamoeba keratitis. Acanthamoeba-specific serum antibody titers and blastogenic responses of peripheral blood lymphocytes were determined weekly. The results indicated that intramuscular injection of Acanthamoeba antigens failed to protect against ocular infection even though hosts developed high titers of IgG antibodies and displayed lymphocyte blastogenic responses to parasite antigens. Ocular infection alone failed to stimulate immunity in any of the animals. By contrast, 50% of the hosts immunized subconjunctivally were protected against corneal disease, and 100% of the animals immunized by a combination of intramuscular and subconjunctival administration of parasite antigens were completely protected against two separate ocular challenges with infectious parasites. Protection did not correlate with either IgG antibody titers or blastogenic potentials of peripheral blood lymphocytes. Interestingly, ocular infection alone failed to stimulate immunity to subsequent ocular challenge with infectious parasites. Thus, administration of parasite antigen via the subconjunctival route can protect against Acanthamoeba keratitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7743802

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  8 in total

Review 1.  The immunobiology of Acanthamoeba keratitis.

Authors:  J Y Niederkorn; H Alizadeh; H F Leher; J P McCulley
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Pattern recognition receptors in microbial keratitis.

Authors:  M-A Taube; M del Mar Cendra; A Elsahn; M Christodoulides; P Hossain
Journal:  Eye (Lond)       Date:  2015-07-10       Impact factor: 3.775

3.  Characterisation and differentiation of pathogenic and non-pathogenic Acanthamoeba strains by their protein and antigen profiles.

Authors:  J Walochnik; K Sommer; A Obwaller; E-M Haller-Schober; H Aspöck
Journal:  Parasitol Res       Date:  2004-01-13       Impact factor: 2.289

4.  Degradation of immunoglobulins, protease inhibitors and interleukin-1 by a secretory proteinase of Acanthamoeba castellanii.

Authors:  Byoung-Kuk Na; Jung-Hwa Cho; Chul-Yong Song; Tong-Soo Kim
Journal:  Korean J Parasitol       Date:  2002-06       Impact factor: 1.341

Review 5.  Acanthamoeba spp. as agents of disease in humans.

Authors:  Francine Marciano-Cabral; Guy Cabral
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

6.  Establishment of an Acanthamoeba keratitis mouse model confirmed by amoebic DNA amplification.

Authors:  Heekyoung Kang; Hae-Jin Sohn; A-Young Park; A-Jeong Ham; Jeong-Heon Lee; Young-Hwan Oh; Yong-Joon Chwae; Kyongmin Kim; Sun Park; Hongseok Yang; Suk-Yul Jung; Jong-Hyun Kim; Ho-Joon Shin
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

7.  Evaluation of three different methods to establish animal models of Acanthamoeba keratitis.

Authors:  Meiyu Ren; Xinyi Wu
Journal:  Yonsei Med J       Date:  2009-12-29       Impact factor: 2.759

Review 8.  The biology of Acanthamoeba keratitis.

Authors:  Jerry Y Niederkorn
Journal:  Exp Eye Res       Date:  2020-11-19       Impact factor: 3.467

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.